ARENA PHARMACEUTICALS INC | 6,133 Euro | -0,035 -0,57 % | |
| WKN: 939027 ISIN: US0400471027 Ticker-Symbol: RN3 | Frankfurt | 21.05.13 | 09:03 Uhr |
Branche PharmaAktienmarkt NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 10.05. | Arena Pharmaceuticals Bearish Moving Average Crossover Alert | 8 | SmarTrend | |
| 10.05. | Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference | 77 | PR Newswire | |
| SAN DIEGO, May 10, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill... Mehr lesen zu: Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference | ||||
| 09.05. | BIOCOM Applauds Arena Pharmaceuticals' Commitment to Innovation, Contributions to Southern California Life Science Community | 49 | PR Newswire | |
| SAN DIEGO, May 9, 2013 /PRNewswire/ -- BIOCOM, the Southern California life science association representing more than 550 member companies, applauds San Diego-based Arena Pharmaceuticals for its... Mehr lesen zu: BIOCOM Applauds Arena Pharmaceuticals' Commitment to Innovation, Contributions to Southern California Life Science Community | ||||
| 08.05. | Option Bulls Jump on Arena Pharmaceuticals, Inc. (ARNA) | 9 | Schaeffer's Research | |
| 07.05. | Arena Pharmaceuticals Rises 10.90% on Heavy Volume: Watch For Potential Pullback | 5 | SmarTrend | |
| 07.05. | UPDATE: Arena Pharma Issues Update on Upcoming US Launch of BELVIQ, to Get $65M Milestone Payment from Eisai | 12 | Benzinga.com | |
| 07.05. | Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ (lorcaserin HCl) for Chronic Weight Management | 77 | PR Newswire | |
| SAN DIEGO, May 7, 2013 /PRNewswire/ --Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's... Mehr lesen zu: Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ (lorcaserin HCl) for Chronic Weight Management | ||||
| 06.05. | Short-term Underperformance Detected in Shares of Arena Pharmaceuticals in the Healthcare Sector | 5 | SmarTrend | |
| 06.05. | Arena Pharma Narrows Loss | 3 | Zacks | |
| 03.05. | Why Arena Pharmaceuticals Shares Slimmed Down | 10 | Motley Fool | |
| 03.05. | Arena Pharmaceuticals Trading Lower on Heavy Volume, Inline With Overall Trend | - | SmarTrend | |
| 03.05. | Arena Pharmaceuticals Shares Sinking Lower, Down 8.4% | - | SmarTrend | |
| 03.05. | Earnings Roundup: Arena Pharmaceuticals, Kraft, ADP | 6 | Barron's | |
| 03.05. | Arena Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript | 13 | Seeking Alpha | |
| 03.05. | Hot Off the Press: Arena Pharmaceuticals' First Quarter Results | 16 | Motley Fool | |
| 02.05. | BRIEF-Arena Pharmaceuticals shares fall 14 pct after the bell following results | 9 | Reuters.com | |
| 02.05. | Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results | 64 | PR Newswire | |
| SAN DIEGO, May 2, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31... Mehr lesen zu: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results | ||||
| 26.04. | Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2 | 43 | PR Newswire | |
| SAN DIEGO, April 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and discuss first quarter 2013 financial results after... Mehr lesen zu: Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2 | ||||
| 25.04. | Arena Pharmaceuticals Crosses Above its 10-day MA | 10 | SmarTrend | |
| 19.04. | The Zacks Analyst Blog Highlights: Microsoft, VIVUS, Arena Pharmaceuticals, Orexigen Therapeutics and UCB | 114 | PR Newswire | |
| CHICAGO, April 19, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting... Mehr lesen zu: The Zacks Analyst Blog Highlights: Microsoft, VIVUS, Arena Pharmaceuticals, Orexigen Therapeutics and UCB | ||||
